{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T05:48:19Z","timestamp":1782712099037,"version":"3.54.5"},"reference-count":31,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T00:00:00Z","timestamp":1782604800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T00:00:00Z","timestamp":1782604800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100017610","name":"Shenzhen Science and Technology Innovation Program","doi-asserted-by":"publisher","award":["KCXFZ20211020172542002"],"award-info":[{"award-number":["KCXFZ20211020172542002"]}],"id":[{"id":"10.13039\/501100017610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzen Municipality","doi-asserted-by":"publisher","award":["SZSM202211030"],"award-info":[{"award-number":["SZSM202211030"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Head &amp; Neck"],"abstract":"ABSTRACT<\/jats:title>\n \n Background<\/jats:title>\n Immunochemotherapy is the standard care of newly diagnosed metastatic nasopharyngeal carcinoma (NPC). Limited trials with small sample sizes reported the potential benefit of delivering radiotherapy in these patients. The purpose of our systematic review and meta\u2010analysis was to examine the efficacy and toxicity of local consolidative radiotherapy when combined with immunochemotherapy as the first\u2010line treatment in newly diagnosed metastatic NPC, providing a reference for clinicians to make the best choice in clinical practice.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n A comprehensive search was conducted in PubMed, Embase, Cochrane Library, Medline, and CNKI to identify published literature between January 1, 2004 and June 30, 2025 to identify potential eligible studies, including patients with pathologically confirmed de novo metastatic NPC treated with radiotherapy and immunochemotherapy. Toxicity rates, progression\u2010free survival (PFS), and overall survival (OS) for the endpoints of interest were extracted from the articles, and the 95% confidence intervals (CIs) were estimated. The systematic review and meta\u2010analysis were conducted in accordance with the PRISMA 2020 Statement, and the study protocol was prospectively registered in PROSPERO (CRD42024607034).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Seven studies with a total of 802 patients were analyzed to evaluate the efficacy and toxicity of first\u2010line local radiotherapy and immunochemotherapy in newly diagnosed metastatic NPC. The results showed that the addition of consolidative radiotherapy to immunochemotherapy significantly improved PFS in de novo metastatic NPC (HR\u2009=\u20090.48 [0.38, 0.60]) using a fixed\u2010effects model (\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u200944%,\n p<\/jats:italic>\n \u2009=\u20090.15). The random\u2010effects pooled result indicated that consolidative radiotherapy added to immunochemotherapy failed to improve OS (HR\u2009=\u20090.52, 95% CI: 0.18\u20131.61,\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u200959%,\n p<\/jats:italic>\n \u2009=\u20090.12). The pooled event rates of toxicities are 62.52% (95% CI: 25.22%\u201392.73%,\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u200997.8%), 63.03% (95% CI: 29.6%\u201390.6%,\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u200997.2%), 57.54% (95% CI: 30.72%\u201382.15%,\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u200995.6%), 21.29% (95% CI: 8.08%\u201339.37%,\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u200991.2%), 7.12% (95% CI: 0.33%\u201321.55%,\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u200987.1%) for mucositis, dermatitis, xerostomia, ear toxicity, and trismus of all grades, respectively. Grade 3\u20134 mucositis, dermatitis, xerostomia, ear toxicity, and trismus were 9.57% (95% CI: 3.37%\u201318.49%,\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u200979.4%), 3.5% (95% CI: 1.87%\u20135.63%,\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u200919.3%), 0.39% (95% CI: 0.01%\u20131.29%,\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u200937.4%), 1.37% (95% CI: 0.01%\u20134.95%,\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u200969.3%), and 0.26% (95% CI: 0%\u20131.25%,\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u20090%), respectively.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Local consolidative radiotherapy combined with immunochemotherapy in de novo metastatic NPC may improve PFS, whereas no statistically significant OS benefit was observed. Of note, the OS finding should be interpreted cautiously given the limited studies available for pooled OS analysis. The pooled toxicity rate derived in this systematic review and meta\u2010analysis can be a guide for clinical decision\u2010making and patient management.<\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/hed.70366","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T05:43:14Z","timestamp":1782711794000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Local Consolidative Radiotherapy Combined With Immunochemotherapy for De Novo Metastatic Nasopharyngeal Carcinoma: A Meta\u2010Analysis"],"prefix":"10.1002","author":[{"given":"Li","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital Fuzhou China"},{"name":"National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital & Shenzhen Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Shenzhen China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangmeng","family":"Fu","sequence":"additional","affiliation":[{"name":"National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital & Shenzhen Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Shenzhen China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxi","family":"Wang","sequence":"additional","affiliation":[{"name":"National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital & Shenzhen Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Shenzhen China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangmei","family":"Zhou","sequence":"additional","affiliation":[{"name":"National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital & Shenzhen Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Shenzhen China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianghu","family":"Zhang","sequence":"additional","affiliation":[{"name":"National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital & Shenzhen Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Shenzhen China"},{"name":"National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sufang","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital Fuzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,28]]},"reference":[{"issue":"10192","key":"e_1_2_13_2_1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal Carcinoma","volume":"394","author":"Chen Y. P.","year":"2019","journal-title":"Lancet"},{"issue":"29","key":"e_1_2_13_3_1","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1200\/JCO.2015.60.9347","article-title":"Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective","volume":"33","author":"Lee A. W.","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"e_1_2_13_4_1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1001\/jamaoncol.2020.1808","article-title":"Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial","volume":"6","author":"You R.","year":"2020","journal-title":"JAMA Oncology"},{"issue":"6","key":"e_1_2_13_5_1","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ccell.2023.04.014","article-title":"Tislelizumab Plus Chemotherapy as First\u2010Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer: A Multicenter Phase 3 Trial (RATIONALE\u2010309)","volume":"41","author":"Yang Y.","year":"2023","journal-title":"Cancer Cell"},{"issue":"8","key":"e_1_2_13_6_1","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","article-title":"Camrelizumab Versus Placebo in Combination With Gemcitabine and Cisplatin as First\u2010Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN\u20101st): A Multicentre, Randomised, Double\u2010Blind, Phase 3 Trial","volume":"22","author":"Yang Y.","year":"2021","journal-title":"Lancet Oncology"},{"issue":"9","key":"e_1_2_13_7_1","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s41591-021-01444-0","article-title":"Toripalimab or Placebo Plus Chemotherapy as First\u2010Line Treatment in Advanced Nasopharyngeal Carcinoma: A Multicenter Randomized Phase 3 Trial","volume":"27","author":"Mai H. Q.","year":"2021","journal-title":"Nature Medicine"},{"key":"e_1_2_13_8_1","unstructured":"National Comprehensive Cancer Network Head and Neck Cancers Version 1.2025 NCCN Clinical Practice Guidelines in Oncology 2024."},{"issue":"8","key":"e_1_2_13_9_1","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1002\/hed.26130","article-title":"Systemic Chemotherapy and Sequential Locoregional Radiotherapy in Initially Metastatic Nasopharyngeal Carcinoma: Retrospective Analysis With 821 Cases","volume":"42","author":"Huang T.","year":"2020","journal-title":"Head & Neck"},{"issue":"5","key":"e_1_2_13_10_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101629","article-title":"Locoregional Radiotherapy Improves Survival Outcomes in De Novo Metastatic Nasopharyngeal Carcinoma Treated With Chemoimmunotherapy","volume":"8","author":"Hu Y. J.","year":"2023","journal-title":"ESMO Open"},{"key":"e_1_2_13_11_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2023.106583","article-title":"Immunochemotherapy Alone or Immunochemotherapy Plus Subsequent Locoregional Radiotherapy in de Novo Metastatic Nasopharyngeal Carcinoma","volume":"147","author":"Liu Z. Q.","year":"2023","journal-title":"Oral Oncology"},{"issue":"11","key":"e_1_2_13_12_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2023.101279","article-title":"Efficacy of Sequential Chemoradiotherapy Combined With Toripalimab in De Novo Metastatic Nasopharyngeal Carcinoma: A Phase II Trial","volume":"4","author":"Chen S. Y.","year":"2023","journal-title":"Cell Reports Medicine"},{"issue":"8","key":"e_1_2_13_13_1","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1002\/hed.27665","article-title":"Loco\u2010Regional Radiotherapy in De Novo Metastatic Nasopharyngeal Carcinoma With Chemotherapy and Immunotherapy: A Real\u2010World Retrospective Study From Two Cancer Centers","volume":"46","author":"Ma L.","year":"2024","journal-title":"Head & Neck"},{"issue":"1","key":"e_1_2_13_14_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-54230-6","article-title":"Risk\u2010Adapted Locoregional Radiotherapy Strategies Based on a Prognostic Nomogram for De Novo Metastatic Nasopharyngeal Carcinoma Patients Treated With Chemoimmunotherapy","volume":"14","author":"Chen Y.","year":"2024","journal-title":"Scientific Reports"},{"issue":"4","key":"e_1_2_13_15_1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.21037\/cco-23-32","article-title":"Treatment Strategy for De Novo Metastatic Nasopharyngeal Carcinoma: A Literature Review","volume":"12","author":"Liu Q.","year":"2023","journal-title":"Chinese Clinical Oncology"},{"key":"e_1_2_13_16_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1467355","article-title":"Immunotherapy Combined With Chemotherapy Without Locoregional Radiotherapy in De Novo Metastatic Nasopharyngeal Carcinoma: Two Case Reports and a Literature Review","volume":"15","author":"Gao Y.","year":"2024","journal-title":"Frontiers in Immunology"},{"key":"e_1_2_13_17_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110687","article-title":"Efficacy of Local\u2010Regional Radiotherapy in de Novo Metastatic Nasopharyngeal Carcinoma Patients Receiving Chemo\u2010Immunotherapy: A Multicenter, Propensity Score Matching Study","volume":"203","author":"He S. Q.","year":"2025","journal-title":"Radiotherapy and Oncology"},{"issue":"11","key":"e_1_2_13_18_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103960","article-title":"Recursive Partitioning Analysis Model for De Novo Metastatic Nasopharyngeal Carcinoma Treated With Locoregional Radiotherapy Following Chemoimmunotherapy","volume":"9","author":"Wen D.","year":"2024","journal-title":"ESMO Open"},{"issue":"1","key":"e_1_2_13_19_1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/ijc.35382","article-title":"Efficacy and Optimal Duration of Maintenance Immunotherapy Following Systemic Chemoimmunotherapy and Locoregional Radiotherapy in de Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Retrospective Cohort Study","volume":"157","author":"Hu Y.","year":"2025","journal-title":"International Journal of Cancer"},{"issue":"1","key":"e_1_2_13_20_1","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-025-03985-4","article-title":"Efficacy and Safety of Cadonilimab (PD\u20101\/CTLA\u20104 Bispecific) in Combination With Chemotherapy in Anti\u2010PD\u20101\u2010Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Single\u2010Arm, Open\u2010Label, Phase 2 Trial","volume":"23","author":"Jiang Y.","year":"2025","journal-title":"BMC Medicine"},{"key":"e_1_2_13_21_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2024.107074","article-title":"Establishing M1 Subdivision for De Novo Nasopharyngeal Carcinoma Patients Receiving Immuno\u2010Chemotherapy: A Multicenter, Retrospective Cohort Study","volume":"159","author":"He S. Q.","year":"2024","journal-title":"Oral Oncology"},{"key":"e_1_2_13_22_1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/hed.27931","article-title":"Evaluating the Reduction of Elective Radiotherapy Fields for De Novo Metastatic Nasopharyngeal Carcinoma in the Immunotherapy Era","volume":"47","author":"Jin T.","year":"2024","journal-title":"Head & Neck"},{"issue":"4","key":"e_1_2_13_23_1","article-title":"Locoregional Radiotherapy Candidates in De Novo Metastatic Nasopharyngeal Carcinoma: Real\u2010World Insights in the Immunotherapy Era","volume":"23","author":"Wen D.","year":"2025","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"8","key":"e_1_2_13_24_1","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.1016\/S1470-2045(19)30157-3","article-title":"Integration of Radiotherapy and Immunotherapy for Treatment of Oligometastases","volume":"20","author":"Pitroda S. P.","year":"2019","journal-title":"Lancet Oncology"},{"issue":"1","key":"e_1_2_13_25_1","first-page":"65","article-title":"Radiotherapy Combination Opportunities Leveraging Immunity for the Next Oncology Practice","volume":"67","author":"Herrera F. G.","year":"2017","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"13","key":"e_1_2_13_26_1","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","article-title":"Radiation and Checkpoint Blockade Immunotherapy: Radiosensitisation and Potential Mechanisms of Synergy","volume":"16","author":"Sharabi A. B.","year":"2015","journal-title":"Lancet Oncology"},{"issue":"7547","key":"e_1_2_13_27_1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and Dual Checkpoint Blockade Activate Non\u2010Redundant Immune Mechanisms in Cancer","volume":"520","author":"Twyman\u2010Saint Victor C.","year":"2015","journal-title":"Nature"},{"issue":"12","key":"e_1_2_13_28_1","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/ncb1507","article-title":"Tumour\u2010Mediated Upregulation of Chemoattractants and Recruitment of Myeloid Cells Predetermines Lung Metastasis","volume":"8","author":"Hiratsuka S.","year":"2006","journal-title":"Nature Cell Biology"},{"issue":"4","key":"e_1_2_13_29_1","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s10555-006-9036-9","article-title":"Bone Marrow Cells in the \u2018Pre\u2010Metastatic Niche\u2019: Within Bone and Beyond","volume":"25","author":"Kaplan R. N.","year":"2006","journal-title":"Cancer Metastasis Reviews"},{"issue":"2","key":"e_1_2_13_30_1","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and Anti\u2010PD\u2010L1 Treatment Synergistically Promote Antitumor Immunity in Mice","volume":"124","author":"Deng L.","year":"2014","journal-title":"Journal of Clinical Investigation"},{"issue":"11","key":"e_1_2_13_31_1","doi-asserted-by":"crossref","first-page":"5874","DOI":"10.4049\/jimmunol.1202612","article-title":"Radiation\u2010Induced Equilibrium Is a Balance Between Tumor Cell Proliferation and T Cell\u2010Mediated Killing","volume":"190","author":"Liang H.","year":"2013","journal-title":"Journal of Immunology"},{"issue":"9","key":"e_1_2_13_32_1","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1002\/hed.26726","article-title":"Identifying the Optimal Candidates for Locoregional Radiation Therapy in Patients With de Novo Metastatic Nasopharyngeal Carcinoma","volume":"43","author":"Xu H.","year":"2021","journal-title":"Head & Neck"}],"container-title":["Head & Neck"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hed.70366","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hed.70366","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hed.70366","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T05:43:20Z","timestamp":1782711800000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hed.70366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,28]]},"references-count":31,"alternative-id":["10.1002\/hed.70366"],"URL":"https:\/\/doi.org\/10.1002\/hed.70366","archive":["Portico"],"relation":{},"ISSN":["1043-3074","1097-0347"],"issn-type":[{"value":"1043-3074","type":"print"},{"value":"1097-0347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,28]]},"assertion":[{"value":"2026-02-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"hed.70366"}}